The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: With the rapid growth in the volume of HIV-related studies that address drug interactions, appropriate medication regimens, and when and how to alter drug regimens, it is challenging for physicians to stay informed. Physicians require knowledge about all drugs taken by HIV patients in order to assess accurately the benefits and risks of various drug combinations.
Objective: To examine the cost and frequency of antiretroviral prescribing errors among a sample of privately insured patients with HIV disease.
Methods: Data were obtained fromthe MarketScan® Commercial Claims and Encounter Database created by the Medstat Group Inc. The MarketScan® database contains claims data for inpatient care, outpatient care, physician services and prescription drugs in benefit plans sponsored by >50 large employers in the US.
This study compared data from the 1999–2000 MarketScan® database with those from the 2005 MarketScan® database. The 2005 MarketScan® database includes 12 226 HIV enrollees who received antiretroviral drugs. This study compared the claims experience of HIV patients who filled a prescription for a drug combination that is not recommended by the US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents with the claims experience of patients who did not receive such a prescription.
Results: In the 1999–2000 database the most common inappropriate drug combination involved the co-administration of a protease inhibitor (PI) and the lipidlowering drug simvastatin, and 1% of patients experienced this type of error.
In the 2005 database, only 0.4% of patients (46 of 12 226) experienced an inappropriate combination of simvastatin and a PI while 5.3% of patients (644 of 12 226) received atazanavir and tenofovir without ritonavir (referred to herein as ‘boosting errors’). Patients who experienced a boosting error incurred higher annual costs than patients who took ritonavir along with tenofovir and atazanavir ($US20 927 vs $US16 704). Because atazanavir was approved by the US FDA in June 2003, medication errors involving atazanavir were not relevant in 1999 and 2000.
Overall, it was found thatHIV patients were three times as likely to experience an inappropriate drug combination in 2005 than they were in either 1999 or 2000 (5.9% vs 1.9%), and that this increase is attributable to boosting errors. In addition, the prevalence rate of HIV in the 2005 MarketScan® database was almost triple that in the 1999 MarketScan® database (0.14% vs 0.05%).
Conclusion: This study indicates that those who provide care to HIV patients must be vigilant in their efforts to provide patients with a drug therapy regimen that minimizes the chance of an adverse reaction and maximizes the potential to control viral replication.
- Chen R, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006 Apr 1; 42: 1003–10 CrossRef
- Sanders GD, Bayoumi AM, Sundaram V, et al. Costeffectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005 Feb 10; 352 (6): 570–85 CrossRef
- Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22: 27–38
- Schackman BR, Goldie SJ, Weinstein MC, et al. Costeffectiveness of earlier initiation of antiretroviral therapy for uninsuredHIV-infected adults. Am J Public Health 2001; 91: 1456–63 CrossRef
- Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Am J Health Sys Pharm 2004 Jun 15; 61 (12): 1242–7
- Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474–8 CrossRef
- Bozzette SA, Berry SH, Duan N, et al. The care of HIV infected adults in the United States. N Engl J Med 1998; 339 (26): 1987–28 CrossRef
- Duggans MG, Evans WN. Estimating the impact of medical innovation: the case of HIV antiretroviral treatments [NBER working paper 1109]. Cambridge (MA): National Bureau of Economic Research, 2005 Feb CrossRef
- Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Washington, DC: US Department of Health and Human Services and the Henry J. Kaiser Family Foundation, 1999 May 5
- Kates J. US federal funding for HIV/AIDS: the FY 2007 request. HIV/AIDS Policy Fact Sheet. Menlo Park (CA): The Henry J. Kaiser Family Foundation, 2006 Feb
- DHHS Panel on AntiretroviralGuidelines for Adults and Adolescents, A Working Group of the Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: NIH, Department of Health and Human Services (DHHS), 2007 Dec 1
- Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society’ USA Panel. JAMA 2000; 283 (3): 381–90 CrossRef
- Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res 1995; 30 (4): 593–614
- Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA 1999; 281 (24): 2305–15 CrossRef
- Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society’ USA panel. JAMA 2002; 286 (2): 222–35 CrossRef
- Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344 (11): 817–23 CrossRef
- Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853–60 CrossRef
- Bates DB, Speil NS, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277 (4): 307–11 CrossRef
- Lesar TS, Lamaestro BM, Pohl H. Medication-prescribing errors in a teaching hospital. Arch Intern Med 1997; 157: 1569–76 CrossRef
- Purdy BD, Raymond AM, Lesar TS. Antiretroviral prescribing errors in hospitalized patients. Ann Pharmacother 2000 Jul/Aug; 34 (7): 833–8 CrossRef
- Edelstein H, Wilson M. Antiretroviral medication errors were universal in hospitalized HIV-seropositive patients at a teaching hospital [letter]. J Acquir Immune Defic Syndr 2001; 28 (5): 496
- Hellinger FJ, Encinosa WE. Inappropriate drug combinations among privately insured patients with HIV disease. Medical Care Sept 2005; 43 (9 Suppl.): 53–62
- Fichtenbaum CJ, Gerber JG, Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16 (4): 569–77 CrossRef
- Donaghy M. Assessing the risk of drug-induced neuorologic disorders: statins and neuoropathy. Neurology 2002; 58 (9): 1321–2 CrossRef
- Ballantyne CM, Corsinis A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163 (5): 553–64 CrossRef
- Stein JH, Wu Y, Kawabata H, et al. Increased use of lipidlowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol 2003; 92: 270–4 CrossRef
- Hulgan T, Sterling TR, Dugherty J, et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 2005; 38 (3): 277–82
- Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2091–6 CrossRef
- Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Washington, DC: DHHS, 2005 Apr 7
- Molto J, Santos J, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit 2007; 29 (5): 648–51 CrossRef
- Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir trough is associated with efficacy and safety: definition of therapeutic range [abstract]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA): 645
- Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1 positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 2005; 56 (2): 380–7 CrossRef
- Adamson DM, Chang S, Hansen LG. Health research data for the real world: the Market Scan databases. Ann Arbor (MI): Thomson Reuters Healthcare, 2008 Jan
- Baser O. Modeling transformed health care cost with unknown heteroskedasticity. Appl Econ Res Bull 2007; 1: 1–6
- CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50 (No. RR-11): 1–52
- CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR 2005; 54 (No. RR-2): 1–20
- Green J, Arno PS. The ‘medicaidization’ of AIDS: trends in the financing of HIV-related medical care. JAMA 1990; 254 (10): 1261–6 CrossRef
- Fasciano NJ, Cherlow AL, Turner B, et al. Profile ofMedicare beneficiaries with AIDS: application of AIDS casefinding algorithm. Health Care Financ Rev 1998; 19 (3): 19–38
- Rosenblum L, Buehler JW, Morgan MW, et al. HIV infection in hospitalized patients and medicaid enrollees: the accuracy of medical record coding. Am J Public Health 1993; 83 (10): 1457–9 CrossRef
- Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40 (5): 609–16 CrossRef
- Mark TL, Coffey RM. What drove private health insurance spending on mental health and substance abuse care, 1992–1999? Health Aff 2003 Jan/Feb; 22 (1): 165–71 CrossRef
- Cohen FJ, Conklin JE, Neslusan CA, et al. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003 Jun; 26 (6): 1847–51 CrossRef
- Gable C, Tierce J, Simison D, et al. Costs of HIV/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr 1996; 12: 413–20 CrossRef
- Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13 (8): 963–9 CrossRef
- Bennett CL, Garfinkle JB, Greenfield S, et al. The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989; 261 (20): 2975–9 CrossRef
- Bennett CL, Adams J, Bennett RL, et al. The learning curve for AIDS-related Pneumocystis carinii pneumonia: experience from 3981 cases in veterans affairs hospitals 1987–1991. J Acquir Immune Defic Syndr 1995; 8 (4): 373–8
- Cunningham WE, Tisnado DM, Lui HH, et al. The effect of hospital experience on mortality among patients hospitalized with Acquired Immune Deficiency Syndrome in California. Am J Med 1999; 107 (2): 137–43 CrossRef
- The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients
Volume 28, Issue 1 , pp 23-34
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links